Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GNTA

Genenta Science SpA ADR

Dec 12 • 12:16PM ET

5.30

Dollar change +0.12
Percentage change 2.42	%

Healthcare • Biotechnology • Italy • NASD

Peers: ALLO NTLA CRSP SRPT BEAM EDIT PSTX SGMO CLLS VYGR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	-	Shs Outstand	18.29M	Perf Week	0.84%
Market Cap	96.94M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-	Shs Float	-	Perf Month	10.19%
Income	-9.65M	PEG	-	EPS next Q	-0.30	Inst Own	5.37%	Short Float	-	Perf Quarter	34.18%
Sales	0.00M	P/S	-	EPS this Y	-32.69%	Inst Trans	0.09%	Short Ratio	0.11	Perf Half Y	55.88%
Book/sh	0.99	P/B	5.38	EPS next Y	9.39%	ROA	-38.96%	Short Interest	0.00M	Perf Year	5.58%
Cash/sh	0.99	P/C	5.35	EPS next 5Y	-	ROE	-42.81%	52W Range	2.20 - 7.28	Perf YTD	7.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.90%	ROI	-53.54%	52W High	-27.20%	Beta	0.74
Dividend TTM	-	Quick Ratio	9.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	140.91%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	9.30	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	56.05	Volatility	3.40% 8.09%
Employees	14	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.62
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	40.36%	Payout	-	Rel Volume	0.07	Prev Close	5.18
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	13.52K	Price	5.30
SMA20	4.81%	SMA50	2.35%	SMA200	29.55%	Trades		Volume	834	Change	2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-23	Resumed	ROTH MKM	Buy	$15
Jul-25-22	Initiated	H.C. Wainwright	Buy	$25
Jan-13-22	Initiated	Maxim Group	Buy	$21

Oct-23-24 07:00AM	Genenta's CEO to present at the U.S. Senate meeting on Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective (GlobeNewswire)
Oct-02-24 06:30AM	Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer (GlobeNewswire) +9.56%
Sep-30-24 05:12AM	Genenta Science S.p.A. (GNTA): Early Investment Opportunity in Innovative Biotech (Insider Monkey) +8.88%
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-06-24 06:25AM	Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider (GlobeNewswire)
05:00AM	Loading…
Feb-08-24 05:00AM	Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors (GlobeNewswire)
Sep-06-23 07:00AM	Genenta to Present at Upcoming Scientific and Investor Conferences (GlobeNewswire)
Jul-28-23 03:00AM	Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments (GlobeNewswire) -6.29%
Jul-08-23 09:57AM	Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation (Simply Wall St.)
Jun-29-23 07:00AM	The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma (GlobeNewswire)
May-17-23 06:34AM	Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company (Simply Wall St.)
May-16-23 07:00AM	Genenta to Provide Update on Lead Product Temferon (GlobeNewswire) +9.80%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 07:00AM	Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing (GlobeNewswire)
07:00AM	Loading…
Apr-03-23 07:00AM	Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications (GlobeNewswire)
Mar-02-23 06:45AM	FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme (GlobeNewswire)
Feb-07-23 07:00AM	Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement (GlobeNewswire)
Jan-29-23 07:45AM	We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Dec-08-22 05:16AM	Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29% (Simply Wall St.)
Nov-07-22 08:05AM	Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon Treatment in Glioblastoma Patients (GlobeNewswire) +8.62%
Oct-24-22 07:30AM	Genenta Provides First Half 2022 Business Update and Financial Results (GlobeNewswire)
Oct-17-22 10:27AM	10 Best Italian Stocks To Buy Now (Insider Monkey)
Oct-05-22 08:05AM	Genenta to Present at Upcoming Scientific and Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Genenta to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-22-22 07:06AM	We're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Rate (Simply Wall St.) -7.38%
Jul-25-22 06:00AM	AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative (GlobeNewswire)
May-27-22 09:40AM	What Kind Of Investors Own Most Of Genenta Science S.p.A. (NASDAQ:GNTA)? (Simply Wall St.) +9.56%
May-13-22 07:30AM	Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA (GlobeNewswire)
May-09-22 07:30AM	Genenta Appoints Industry Veteran Tim Obara as Head of Business Development (GlobeNewswire)
04:30PM	Loading…
May-04-22 04:30PM	Genenta Files Annual Report on Form 20-F for Fiscal Year 2021 (GlobeNewswire)
07:30AM	Genenta Progresses to Higher Dosing Cohort in Temferon Phase 1/2a Clinical Trial in Glioblastoma Multiforme (GlobeNewswire)
May-02-22 04:30PM	Genenta ASGCT Clinical Data Highlights Temferon Biological Effects in Glioblastoma (GlobeNewswire) +5.52% -10.29%
Apr-27-22 07:30AM	Genenta Announces Nomination of Mark A. Sirgo as Chair (GlobeNewswire)
Apr-20-22 07:30AM	Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors (GlobeNewswire)
Mar-15-22 06:34AM	Is Genenta Science (NASDAQ:GNTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +5.89%
Mar-09-22 07:46AM	Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon in Unmethylated Glioblastoma Multiforme (GlobeNewswire)
Feb-24-22 07:30AM	Genenta to Participate at Upcoming Investor Conferences (GlobeNewswire) -11.37%
Dec-17-21 04:15PM	Genenta Closes Its Upsized Initial Public Offering of American Depository Shares (GlobeNewswire)
Dec-14-21 10:36PM	Genenta Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNTA

Genenta Science SpA ADR

Upgrade your FINVIZ experience